Literature DB >> 35693878

Gut viruses firm the "Great Wall".

Anmin Wang1, Shu Zhu1,2,3.   

Abstract

Entities:  

Year:  2019        PMID: 35693878      PMCID: PMC8985767          DOI: 10.1093/pcmedi/pbz027

Source DB:  PubMed          Journal:  Precis Clin Med        ISSN: 2516-1571


× No keyword cloud information.
Emerging evidences shows that gut viruses are involved in many physiological processes and are detrimental to human health. A recent study published in Nature Immunology describes a novel function of intestinal commensal viruses, maintaining the intestinal intraepithelial lymphocytes (IELs) numbers in the intestine to firm the “great wall” to protect the host against the pathogen invasion (Fig. 1).
Figure 1

Intestinal commensal viruses help to firm the “Great Wall” against pathogens by maintaining the intestinal intraepithelial lymphocytes (IELs) numbers in the intestine.

There are 1013 bacteria and 1014 viruses living in the gut. Numerous studies investigated the composition of commensal bacteria, and their physiological and pathological functions. However, little is known for the role of commensal viruses in the intestine because of limit tools and lack of attention. Recently, emerging evidences shows commensal viruses also play important roles in the intestine. In 2003, about 1200 types of viruses in gut were first detected by shotgun method. Subsequently, metagenomics studies have revealed a bunch of viral components in the microbiome. As the consequence of the sequencing studies, we now know the intestinal virome is composed of eukaryotic viruses, prokaryotic viruses and endogenous retroviruses. The commensal viruses in the gut is associated with human health and diseases. They benefit the host while in certain circumstances they are opportunistically pathogenic. Kernbauer et al highlighted the beneficial function of commensal viruses showing they contribute to the development of intestinal epithelial cells. They found murine norovirus (MNV) protects antibiotics-treated mice from DSS-induced enteritis dependent on IFNAR1 and MNV infects tuft cells, which contributes to type 2 immune responses. Furthermore, they demonstrate that MNV provides a striking IL-22-dependent protection against early-life lethal infection by Citrobacter rodentium. Because norovirus RNA is detected in up to 16% of healthy humans, it is necessary to explore asymptomatic enteric viral infections and the potential effect on human health. Researchers focused on composition and function of intestinal virome and tried to explore the relationship between intestinal virus and diseases such as inflammatory bowel disease (IBD) and type I diabetes. In addition they also explored the immunology, structure, and pathogenesis of enterovirus like Norovirus. Intestinal commensal viruses help to firm the “Great Wall” against pathogens by maintaining the intestinal intraepithelial lymphocytes (IELs) numbers in the intestine. IBDs, including Crohn’s disease (CD) and ulcerative colitis (UC), are chronic diseases with persistent intestinal inflammation. Disease-specific changes in enteric virome occur in both CD and UC. Compared with control, there is a higher virus diversity and phage-related abundance (mainly Caudoviridaes and Microviridae in IBD fecal virions) in feces or biopsy tissues of newly diagnosed IBD/CD patients. Epstein-Barr virus (EBV) and human cytomegalovirus (HCMV) infection usually occur in childhood, and healthy people show no symptoms after the infection. However, these viruses may live with the host for lifelong, and they were considered as the risk factor of the IBD. More and more basic and clinical studies have provided evidences that support the close relationship between intestinal commensal viruses and the immune system. However, how these viruses are sensed by immune system in the gut as well as the immune outcome of the viral sensing in the gut is still unknown. In a recent study published in Nature Immunology, Liu et al. demonstrated that under physiological conditions, intestinal commensal viruses are sensed by innate recognition receptor Rig-I, triggering the activation of IRF1/IL-15 pathway to maintain intestinal intraepithelial lymphocyte (IELs) numbers in the intestine. First of all, Liu et al. used metagenomics sequencing to confirm the presence of large numbers of phage and eukaryotic viruses in the gut of specific pathogen-free (SPF) mice. Using an antiviral cocktails (AVC) to deplete the intestinal commensal viruses, they found that the number of IELs especially CD8αβ + TCRβ+ and CD8αα + TCRβ+ cells in the AVC-treated group was significantly reduced. However, there was no significant change in the number and proportion of immune cells in other organs such as spleen or liver in AVC treated mice. The above results indicate that intestinal commensal viruses are important for maintaining IELs homeostasis. Subsequently, to explore how the intestinal commensal virus is perceived by the body and regulates the IELs homeostasis, the researchers used a variety of natural immune recognition receptors and their adaptors-deficient mice to analyze the proportion and number of intestinal IELs subsets. They found that the deficiency of intracellular RNA sensor RIG-I (Ddx58−/−) and its downstream adaptor protein MAVS (Mavs−/−) result in significantly reduced IELs in the intestine of the mice, which exactly phenocopy AVC treated mice, suggesting that intestinal commensal virus maintains the IELs homeostasis by activating the RIG-I signaling. Furthermore, the researchers used bone marrow chimeric experiments and conditional knock out mice to verify that the RIG-I signal in lamina propria antigen-presenting cells (APCs) maintained IELs homeostasis. The authors next tried to figure out the downstream pathway how Rig-I signaling in APC such as DCs maintains the IELs in the gut. The authors first excluded the participation of type I interferon (IFN-I) as Ifnar1−/− mice didn’t show the IEL loss phenotype. Instead, the authors found a much lower level of IL-15 in APCs from Ddx58−/− mice and AVC treated mice, which might be responsible for the IELs loss phenotype. Next, the authors found IRF-1, which control IL-15 production and is also activated by RIG-I-MAVS, can maintain IELs numbers. Irf1−/−mice have the same IELs loss phenotype with Ddx58−/− mice, and administration of IL-15 rescue the IEL loss phenotype in these mice, showing the importance of commensal virus/Rig-I/Mavs/IRF1/IL-15 signaling cascade in IEL maintenance. Since IELs as well as intestinal epithelial cells (IECs) act as the first line of defense against the numerous microbes in the gut lumen, the authors tested that whether the maintenance of IEL homeostasis by commensal viruses contribute to intestinal tissue damage and inflammation. Ddx58−/− mice as well as virus-depleted mice showed more severe colitis during DSS treatment. AAV-mediated IL-15 delivery rescue the severer colitis phenotype of AVC treated mice and Mavs−/− mice, suggesting that Rig-I sensing of commensal viruses is important for the barrier function of intestine. Recent years witnessed fast growing researches on enteroviruses, including pathogenic viruses, commensal viruses and opportunistically pathogenic viruses. Sequencing, culturing, and examination of the precise role of them in health and disease will help provide novel diagnosis markers or therapies. However, there are still some major challenges in this field. First, there is still lack of tools to study intestinal virome composition and function. A more thorough examination of the virome with more advanced viral particle (both DNA and RNA viruses) isolation and sequencing methods as well as the establishment of the virus reference database is essential. More specific depletion method of different types of the viruses, as well as the advanced culture methods is also needed to study their precise role in health and diseases. Second, the commensal viruses are not the only player in the intestine. Besides our current studies on immune-virome crosstalk in intestine, the thorough evaluation of the interaction between virome and other members of the intestinal microbiota, such as bacteria and fungi, is needed to understand the complexity of transkingdom interaction among virome, other microbes, and host. Third, like bacteria in the microbiota, the composition of the intestinal virome is dynamic. How it changes over time is essential to evaluate its impact on human health. Will daily diets and circadian rhythm affect the virome composition or function? Will it change along the year or the whole life? More studies are needed to address these questions. Finally, intestinal virome research needs an application-reorientation. With the accumulation of the knowledge of transkingdom interaction among virome, other microbes, and host, the targeted therapies became more realistic. For example, treatment with bacterial flagellin or IFNλ cure the rotavirus and MNV infection,. Also, bacteria phages are used to treat antibiotic resistant bacterial infection or alcoholic liver disease,. Moreover, some enteroviruses may benefit host via immune-regulating signals, indicating possibilities to design enteric viruses with desirable characteristics to treat human infection, inflammation or cancer conditions, e.g. current attempts at oncolytic virus treatment of tumor. In summary, identification and characterization of the beneficial or pathogenic enteric viruses may improve our understanding of the role of microbiota on human health and diseases, and may lead to novel diagnosis and therapies.
  19 in total

Review 1.  The Intestinal Microbiota in Inflammatory Bowel Disease.

Authors:  Christoph Becker; Markus F Neurath; Stefan Wirtz
Journal:  ILAR J       Date:  2015

2.  Looking into Enteric Virome in Patients with IBD: Defining Guilty or Innocence?

Authors:  Susana Lopes; Patricia Andrade; Silvia Conde; Rodrigo Liberal; Cláudia C Dias; Salomão Fernandes; Jorge Pinheiro; Joana S Simões; Fátima Carneiro; Fernando Magro; Guilherme Macedo
Journal:  Inflamm Bowel Dis       Date:  2017-08       Impact factor: 5.325

Review 3.  Redefining chronic viral infection.

Authors:  Herbert W Virgin; E John Wherry; Rafi Ahmed
Journal:  Cell       Date:  2009-07-10       Impact factor: 41.582

4.  Microbiota Diurnal Rhythmicity Programs Host Transcriptome Oscillations.

Authors:  Christoph A Thaiss; Maayan Levy; Tal Korem; Lenka Dohnalová; Hagit Shapiro; Diego A Jaitin; Eyal David; Deborah R Winter; Meital Gury-BenAri; Evgeny Tatirovsky; Timur Tuganbaev; Sara Federici; Niv Zmora; David Zeevi; Mally Dori-Bachash; Meirav Pevsner-Fischer; Elena Kartvelishvily; Alexander Brandis; Alon Harmelin; Oren Shibolet; Zamir Halpern; Kenya Honda; Ido Amit; Eran Segal; Eran Elinav
Journal:  Cell       Date:  2016-12-01       Impact factor: 41.582

5.  Interferon-λ cures persistent murine norovirus infection in the absence of adaptive immunity.

Authors:  Timothy J Nice; Megan T Baldridge; Broc T McCune; Jason M Norman; Helen M Lazear; Maxim Artyomov; Michael S Diamond; Herbert W Virgin
Journal:  Science       Date:  2014-11-27       Impact factor: 47.728

Review 6.  T lymphocytes in the intestinal mucosa: defense and tolerance.

Authors:  Hongdi Ma; Wanyin Tao; Shu Zhu
Journal:  Cell Mol Immunol       Date:  2019-02-20       Impact factor: 11.530

7.  An enteric virus can replace the beneficial function of commensal bacteria.

Authors:  Elisabeth Kernbauer; Yi Ding; Ken Cadwell
Journal:  Nature       Date:  2014-11-19       Impact factor: 49.962

8.  IFN-I and IL-22 mediate protective effects of intestinal viral infection.

Authors:  Jessica A Neil; Yu Matsuzawa-Ishimoto; Elisabeth Kernbauer-Hölzl; Samantha L Schuster; Stela Sota; Mericien Venzon; Simone Dallari; Antonio Galvao Neto; Ashley Hine; David Hudesman; P'ng Loke; Timothy J Nice; Ken Cadwell
Journal:  Nat Microbiol       Date:  2019-06-10       Impact factor: 17.745

Review 9.  The disparate effects of bacteriophages on antibiotic-resistant bacteria.

Authors:  Clara Torres-Barceló
Journal:  Emerg Microbes Infect       Date:  2018-10-10       Impact factor: 7.163

Review 10.  Oncolytic viruses: a new class of immunotherapy drugs.

Authors:  Howard L Kaufman; Frederick J Kohlhapp; Andrew Zloza
Journal:  Nat Rev Drug Discov       Date:  2015-09       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.